Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares news (Ticker: $IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares's position in the market.
News
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announces an Investor Presentation to reveal a major milestone regarding their breakthrough Augmented Respiration Technology. The technology aims to rebalance patient oxygen levels without invasive ventilation systems. The Company President, Mr. Joe Hayon, will present the details on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.42%
Tags
-
Rhea-AI Summary
Inspira Technologies progresses towards FDA 510(k) clearance for INSPIRA ART100 device, plans additional submissions for HYLA blood sensor and INSPIRA ART disposables. Company revolutionizing mechanical ventilator market with proprietary technologies. Signed $546 million in distribution agreements. President emphasizes the importance of HYLA blood sensor in delivering oxygen. Breakthrough patents approved by USPTO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.42%
Tags
-
Rhea-AI Summary
Inspira Technologies unveils breakthrough blood simulation capability to advance medical technologies. The platform aims to reduce time and costs, accelerate development, and improve validation processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
News
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. receives U.S. Patent approval for orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART500 device. The system is designed to revolutionize medical oxygenation by eliminating damage caused by fiber membranes. CEO Dagi Ben-Noon hails it as a monumental advancement in blood oxygenation technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.42%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has announced a non-binding Letter of Intent (LOI) with Shamir Medical Center to assess the integration and performance of the INSPIRA™ ART100 device within the hospital's clinical environment. The LOI solidifies the mutual commitment of both parties to evaluate the device's fit, efficiency, and overall impact on healthcare delivery. The collaboration aims to enhance life-support care and establish a pathway for adoption in local and international markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has announced a summary distribution agreement with Glo-Med Networks, Inc. to potentially provide $32.6 million over a 5-year period. The agreement designates Glo-Med as the exclusive distributor in Saudi Arabia, United Arab Emirates, and Bahrain for the INSPIRA™ ART devices. The agreement is subject to regulatory approvals and is seen as a significant step for both companies in broadening their range of innovative products in the healthcare market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) announces the development of a single-use disposable blood oxygenation kit for its INSPIRA ART medical device series, targeting FDA authorization in 2025. The kit is designed to be compatible with various life support machines, potentially reducing hospital costs. CEO Dagi Ben-Noon anticipates revenue streams based on the disposable razorblade business model, along with the FDA clearance of the INSPIRA™ ART100 device in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital, a top-ranked hospital in the United States, to explore collaboration for the evaluation of its INSPIRA ART100 device. The agreement is subject to FDA clearance and entering a definitive evaluation agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has closed a registered direct offering of 3,031,250 ordinary shares at a purchase price of $1.28 per share, with aggregate gross proceeds of approximately $3.88 million. The company also issued warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) has entered into a definitive agreement for the issuance and sale of 3,031,250 ordinary shares at a purchase price of $1.28 per share in a registered direct offering. The company will also issue unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares
Nasdaq:IINN
IINN Rankings
IINN Stock Data
38.22M
9.57M
9.47%
9.3%
1.39%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Raanana
About IINN
insense medical develops state of the art respiratory support technology as an alternative to mechanical ventilation by 2020 more than 600,000 patients in the u.s. will require mechanical ventilation. 5.7 million patients are admitted annually to icu's with 35% needing ventilation. cost of treatment is estimated at 64 bn$/y as mortality reaches 40%. imagine that instead of mechanical ventilation, or ecmo treatment, a small and safe apparatus is placed into a vein, replacing necessary lung functions without the devastating complications associated with mechanical ventilation. oxylink, an advanced nano vesicle technology. our revolutionary intravascular oxygenation apparatus, safely increases the level of oxygen & reduces the carbon dioxide in blood, enabling your physician to address the primary ventilatory condition.